Puray

This content was machine translated.

About Puray

Hospital-acquired infections are among the most pressing problems in healthcare. According to Germany’s RKI, 10,000–20,000 patients die annually from infections acquired in hospitals. Infections caused by multidrug-resistant pathogens are a particular challenge. One of the most common forms of hospital-acquired infection is “device-associated infection.” These occur when pathogens enter the body via medical tubes, such as catheters or probes. Device-associated infections rank among the most frequent, costly, and dangerous forms of hospital-acquired infections. Puray is developing a medical catheter that actively prevents hospital-acquired infections. Our product emits UVC light at a specific wavelength that kills pathogens without damaging human cells. For the first time, this enables the catheter to be safely and continuously disinfected during use, protecting patients from infections. The technology reduces the need for antibiotics and remains effective even against multidrug-resistant pathogens. We aim to apply our innovation to other medical tubes in the future, such as ventilation tubes, cardiac catheters, and vascular catheters, thereby preventing a large proportion of all hospital-acquired infections.

Discover more articles, startups, and events from the ecosystem

Ecosystem

Munich startups win at Generation-D

09.10.25

1 Min.

Ecosystem

Puray receives Signal Iduna Award 2023

11.12.23

2 Min.

Ecosystem

Puray wins Health-i Award 2022

13.09.22

2 Min.

Conference

Startups for Tomorrow Festival 2026

September 15, 2026

09:00 AM – 07:00 PM

smartvillage Bogenhausen, Munich

Workshop

How to Turn Your Communication into a Strategic Asset

September 15, 2026

10:00 AM – 11:30 AM

gate – Garchinger Technologie- und Gründerzentrum GmbH, Garching bei München

Air2Growth

Air2Growth is developing an innovative system that converts CO2 emissions directly on-site into high-quality organic fertilizer. Using advanced microalgae technology, we create a closed circular economy that enables more sustainable, independent, and economical agriculture. Our solution specifically targets greenhouse operators as well as modern agricultural businesses. By directly utilizing exhaust gases and CO2 sources, our customers not only actively lower their environmental footprint, but also noticeably reduce their ongoing fertilizer costs at the same time. In times of fluctuating market prices and uncertain supply chains, Air2Growth makes businesses independent of fossil raw materials and synthetic imports. In this way, we combine effective climate protection with concrete economic benefits and strengthen the future viability of regional food production.

NeoSoma

At NeoSoma, we empower individuals by restoring full control over their health data. Our open-access tracker ensures that users own their data and decide precisely who may access them – without subscription barriers or vendor lock-in. For research our device provides raw signal output, configurable sampling rates and duty cycles, and full transparency of sensor streams. We believe that health tracking should serve the individual first – your body, your data, your decisions – while offering the same professional-grade foundation for science and discovery.

rnhale

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challenges of pulmonary RNA delivery, stability, deep lung deposition, and cellular uptake, our technology unlocks a more effective path for RNA-based therapies to reach their target. Our goal is to develop effective, locally-acting respiratory therapies that address disease at its molecular source. Our vision: to redefine the treatment of severe lung diseases.